Prostate Cancer Reports


Volume 2 Supplement 5
 May 2014
Home > Prostate Cancer Reports > Volume 2 - Year 2014 > Supplement 5, May 2014

CONTENTS



Diagnosis and evaluation
Recurrence
Staging
Treatment





Ghafoori M, Alavi M, Aliyari Ghasabeh M.
MRI in prostate cancer.
Iran Red Crescent Med J. 2013 Dec;15(12):e16620. doi: 10.5812/ircmj.16620. Epub 2013 Dec 5.
Abstract | Full text | Related citations



Biochemical recurrence

Abdollah F, Briganti A.
Reply to Chris Parker, Matthew R. Sydes and Howard Kynaston's letter to the editor re: Firas Abdollah, Nazareno Suardi, Cesare Cozzarini, et al. Selecting the optimal candidate for adjuvant radiotherapy after radical prostatectomy for prostate cancer: a long-term survival analysis. Eur Urol 2013;63:998-1008.
Eur Urol. 2013 Nov;64(5):e103-4. doi: 10.1016/j.eururo.2013.07.028. Epub 2013 Jul 27.
Abstract | Full text | Related citations


Chen RC.
Making individualized decisions in the midst of uncertainties: the case of prostate cancer and biochemical recurrence.
Eur Urol. 2013 Dec;64(6):916-8; discussion 918-9. doi: 10.1016/j.eururo.2013.07.001. Epub 2013 Jul 9.
Abstract | Full text | Related citations


Ghadjar P, Aebersold DM.
Re: Andrew J. Stephenson, Michel Bolla, Alberto Briganti, et al. Postoperative radiation therapy for pathologically advanced prostate cancer after radical prostatectomy. Eur Urol 2012;61:443-51.
Eur Urol. 2012 Apr;61(4):e39. doi: 10.1016/j.eururo.2011.11.054. Epub 2011 Dec 7.
Abstract | Full text | Related citations


Kibel AS.
Treat now or later: the dilemma of postoperative radiotherapy.
Eur Urol. 2012 Mar;61(3):452-4. doi: 10.1016/j.eururo.2011.11.044. Epub 2011 Dec 3.
Abstract | Full text | Related citations


Parker C, Sydes MR, Kynaston H; RADICALS Investigators.
Re: Sanoj Punnen, Matthew R. Cooperberg, Anthony V. D'Amico, et al. Management of biochemical recurrence after primary treatment of prostate cancer: a systematic review of the literature. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2013.05.025: Re: Firas Abdollah, Nazareno Suardi, Cesare Cozzarini, et al. Selecting the optimal candidate for adjuvant radiotherapy after radical prostatectomy for prostate cancer: a long-term survival analysis. Eur Urol 2013;63:998-1008.
Eur Urol. 2013 Nov;64(5):e102. doi: 10.1016/j.eururo.2013.07.029. Epub 2013 Jul 26.
Abstract | Full text | Related citations


Punnen S, Cooperberg MR, D'Amico AV, Karakiewicz PI, Moul JW, Scher HI, Schlomm T, Freedland SJ.
Management of biochemical recurrence after primary treatment of prostate cancer: a systematic review of the literature.
Eur Urol. 2013 Dec;64(6):905-15. doi: 10.1016/j.eururo.2013.05.025. Epub 2013 May 16.
Abstract | Full text | Related citations


Punnen S, Cooperberg MR, Freedland SJ.
Reply from Authors re: Ronald C. Chen. Making Individualized Decisions in the Midst of Uncertainties: The Case of Prostate Cancer and Biochemical Recurrence. Eur Urol 2013;64:916–8: Optimal Timing for Postoperative Radiation: Still an Unanswered Question.
European Urology, Volume 64, Issue 6, December 2013, Pages 918-919
.
Abstract | Full text |
Related citations


Stephenson AJ, Bolla M, Briganti A, Cozzarini C, Moul JW, Roach M 3rd, van Poppel H, Zietman A.
Postoperative radiation therapy for pathologically advanced prostate cancer after radical prostatectomy.
Eur Urol. 2012 Mar;61(3):443-51. doi: 10.1016/j.eururo.2011.10.010. Epub 2011 Oct 21.
Abstract | Full text | Related citations


Sydes MR, Vale C, Kneebone A, Pearse M, Richaud P, Tierney JF, Parker CC.
Re: Andrew J. Stephenson, Michel Bolla, Alberto Briganti, et al. Postoperative radiation therapy for pathologically advanced prostate cancer after radical prostatectomy. Eur Urol 2012;61:443-51.
Eur Urol. 2012 Dec;62(6):e99. doi: 10.1016/j.eururo.2012.09.003. Epub 2012 Sep 11.
Abstract | Full text | Related citations



Gleason score

Ellis WJ.
Treating prostate cancer: where do we draw the line?
Oncology (Williston Park). 2014 Jan;28(1):29, 32.
Abstract | Full text | Related citations


Iczkowski KA, La Rosa FG.
Gleason 6 cancer is still cancer.
Oncology (Williston Park). 2014 Jan;28(1):22, 24, 29
Abstract | Full text | Related citations



Lepor H, Donin NM.
Gleason 6 prostate cancer: serious malignancy or toothless lion?
Oncology (Williston Park). 2014 Jan;28(1):16-22.
Abstract | Full text | Related citations



Treatment decision making

Bahl A, Masson S, Birtle A, Chowdhury S, de Bono J.
Second-line treatment options in metastatic castration-resistant prostate cancer: a comparison of key trials with recently approved agents.
Cancer Treat Rev. 2014 Feb;40(1):170-7. doi: 10.1016/j.ctrv.2013.06.008. Epub 2013 Aug 16
Abstract | Full text | Related citations


Fitzpatrick JM, Bellmunt J, Fizazi K, Heidenreich A, Sternberg CN, Tombal B, Alcaraz A, Bahl A, Bracarda S, Di Lorenzo G, Efstathiou E, Finn SP, Fosså S, Gillessen S, Kellokumpu-Lehtinen PL, Lecouvet FE, Oudard S, de Reijke TM, Robson CN, De Santis M, Seruga B, de Wit R.
Optimal management of metastatic castration-resistant prostate cancer: highlights from a European Expert Consensus Panel.
Eur J Cancer. 2014 Jun;50(9):1617-27. doi: 10.1016/j.ejca.2014.03.010. Epub 2014 Apr 3.
Abstract | Full text | Related citations